بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), clinical areas (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), clinical areas (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
-
2861
-
2862
-
2863
-
2864
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
منشور في 2024الموضوعات: -
2865
Bar graphs showing the means and 95% CI of each retinal layer thickness at each visit.
منشور في 2025الموضوعات: -
2866
-
2867
-
2868
-
2869
-
2870
-
2871
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
2872
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
2873
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
منشور في 2025"…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…"
-
2874
Baseline Characteristics of Study Participants.
منشور في 2025"…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …"
-
2875
Raw and processed data files.
منشور في 2025"…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …"
-
2876
-
2877
-
2878
-
2879
-
2880
Effects of busulfan treatment (6 mg/kg) on the body and testes weights of mice over three weeks.
منشور في 2025الموضوعات: